Bone Biologics Corp
No enriched coverage for $BBLG in the last 7 days.
No SEC Form 4 filings for $BBLG in the last 30 days.
See all $BBLG insider activity →Bone Biologics (BBLG) said it extended the validated shelf life of its rhNELL-1 protein to 32 months, citing improved manufacturing, storage, and distribution flexibility for its lead candidate NB1. CEO Jeff Frelick linked the milestone to readiness for ongoing NB1 first-in-human work. The stock was last at $0.65, down 28% and at a 52-week low.
Bone Biologics (Nasdaq: BBLG, BBLGW) issued a shareholder update on NB1 progress in 1H 2026. The company completed a private placement in July 2026 raising about $3.0 million gross, with warrants that could add up to about $6.0 million if exercised. It said rhNELL-1 shelf life was extended to 29 months and it expects NB1 first-in-human enrollment completion by year-end.
Bone Biologics Corp (BBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 7, 2026, between Bone Biologics Corporation, a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur
Recent BBLG coverage spans corporate actions, financial news and technology.
The shelf-life extension is a practical development and supply-chain milestone that can reduce logistics risk and improve lot sizing for NB1.
Financing and runway extension reduce near-term funding risk, supporting continued NB1 clinical execution into 2027.
The filing indicates BBLG has entered a material definitive agreement to issue and sell securities, which can dilute shareholders and affect near-term liquidity/financing risk.
The dilutive financing and warrant structure are likely to pressure near-term valuation, while funding supports clinical and IP plans.
Dilutive equity/warrant financing at $1.42 is likely to pressure near-term valuation, while funding supports clinical trials and working capital.
alphai scores every news story that mentions BBLG with an AI model for sentiment and relevance, and aggregates insider trades from Bone Biologics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bone Biologics (BBLG) said it extended the validated shelf life of its rhNELL-1 protein to 32 months, citing improved manufacturing, storage, and distribution flexibility for its lead candidate NB1. CEO Jeff Frelick linked the milestone to readiness for ongoing NB1 first-in-human work. The stock was last at $0.65, down 28% and at a 52-week low.
3 min readBone Biologics (Nasdaq: BBLG, BBLGW) issued a shareholder update on NB1 progress in 1H 2026. The company completed a private placement in July 2026 raising about $3.0 million gross, with warrants that could add up to about $6.0 million if exercised. It said rhNELL-1 shelf life was extended to 29 months and it expects NB1 first-in-human enrollment completion by year-end.
4 min readBone Biologics Corp (BBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 7, 2026, between Bone Biologics Corporation, a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur
6 min readBone Biologics (BBLG) said it will sell 2.11M shares or pre-funded warrants plus Series F and short-term Series G warrants to a single institutional investor at $1.42 per share. Gross proceeds are expected at about $3M, with up to about $6M more if warrants are exercised. Net proceeds will fund trials, patents, and working capital. Closing expected July 9, 2026.
3 min readBone Biologics (Nasdaq: BBLG) announced a private placement priced at-the-market under Nasdaq rules with a single healthcare institutional investor. It will issue 2,112,677 shares (or pre-funded warrants) plus Series F and short-term Series G warrants at $1.42/share. Gross proceeds are ~$3.0M upfront, up to ~$6.0M if warrants are fully exercised. Net proceeds fund clinical trials, patents, and working capital; closing expected July 9, 2026.
3 min readBone Biologics Corp (BBLG) stocks have seen a 10.33% increase due to advancements in spinal therapies, despite recent financial reports indicating declines in net income and total assets. The company is at a crucial juncture, balancing promising product development with financial challenges. While market volatility exists, the company's strong balance sheet and focus on strategic adjustments offer potential for future gains, urging investors to weigh product innovation against cost pressures.
3 min readBone Biologics' trading volume surged to 17.22M, far above its 38.8K average. The company expects $5 million from the offering, with up to $10 million more if warrants are exercised. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
2 min read
